LONDON, May 9, 2016 /PRNewswire/ --
Forecasts from 2016-2026 and other analyses show you commercial prospects Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments.
See detailed profiles or revenue forecasts for some of the leading regions in the generic drugs market US EU5 Asia-Pacific Emerging markets
See revenue forecasts for the leading international markets How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets, including: US Germany UK France Italy Spain China Japan India Brazil Russia Mexico South Korea Turkey
To see a report overview please email Sara Peerun on [email protected]
Leading companies and potential for market growth Visiongain forecasts overall revenue for the Generic Drugs Market will reach $254.6bn in 2016. We predict a high revenue growth over the forecast period driven by an ageing population, healthcare cost saving strategies and rapid growth of emerging economies.
Our work analyses the key companies in the market. See visiongain's analysis of ten leading companies, including: Teva Novartis (Sandoz) Allergan Mylan Pfizer Abbott Sun Pharma Aspen Fresenius Kabi Sanofi
A company profile gives you the following information where available: Discussion of a company's activities and outlook Generic drugs revenue and share of total revenue Historic revenue (where available), analysis and discussion of company performance Analysis of major products currently on the market Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the generic drugs industry? Our new report discusses issues and events affecting the generic drugs market. You will find discussions, including qualitative analyses: Highly fragmented and competitive market with significant variations in different geographic regions Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities Future generic drug opportunities
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets report helps you In summary, our 306-page report gives you the following knowledge: Revenue forecasts to 2026 for the Generic Drugs market - discover the industry's prospects, finding promising places for investments and revenues Revenue forecasts to 2026 for major regional markets - US, EU5, Asia-Pacific, Emerging markets Revenue forecasts to 2026 for fourteen leading national markets - US, Germany, UK, France, Italy, Spain, China, Japan, India, Brazil, Russia, Mexico, South Korea and Turkey Assessment of leading companies - analysis of products, revenue (where available), mergers & acquisitions, and pipelines Discussion of what stimulates and restrains companies and the market Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the generic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.
To see a report overview please email Sara Peerun on [email protected]
To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100
Or click on https://www.visiongain.com/Report/1630/Generic-Drugs-Market-Forecast-2016-2026
Companies Mentioned in the Report
Abbott
AbbVie
Actavis
Alcon (Novartis)
Allergan (Actavis)
Amgen
Anda Inc
APP Pharmaceuticals
Arrow Group (Actavis)
Ascent Pharmahealth (Actavis)
ASKA Pharmaceuticals
Aspen
AstraZeneca
Bergamo (Amgen)
Bioniche Pharma (Mylan)
BMP Sunstone (Sanofi)
CFR Pharmaceuticals (Abbott)
Cipla
Dabur Pharma (Fresenius Kabi)
Daiichi Sankyo
Dalim BioTech
Dr Reddy's Laboratory
Ebewe Pharma (Novartis)
Eden Biopharm Group
Egis
Elder Pharmaceuticals (Torrent Pharmaceuticals)
Eli Lilly
Elyson Pharmaceuticals
EMS Sigma Pharma
Eurofarma Laboratories
Farmacias Similares
Fenwal (Fresenius Kabi)
Forest Laboratories (Actavis)
Foshan Chanbende Development
Fougera Pharmaceuticals (Novartis)
Fresenius Kabi
Fresenius SE & Co
Fuji Pharma
Gedeon Richter
Genfar S.A (Sanofi)
Genzyme (Sanofi)
Gilead Sciences
GlaxoSmithKline (GSK)
Greenstone (Pfizer)
Grupo Sanborns
Grupo Uriach
Hospira (Pfizer)
IDEV Technologies (Abbott)
Ilsung Pharmaceuticals
InnoPharma Inc
Itero Biopharmaceuticals
Janssen
Javelin Pharmaceuticals (Hospira)
Kmart
KMS Pharmaceutical
Kowa Pharmaceuticals
Krka
Labesfal Genιricos (Fresenius Kabi)
Laboratorio Sanderson (Fresenius Kabi)
Laboratorios Best
Laboratorios Kendrick (Sanofi)
Lek (Novartis)
Lupin
Mayne Pharma (Hospira)
Medley (Sanofi)
Merck KGaA
MN Pharma (Amgen)
Momenta Pharmaceuticals
Mylan
Natco Pharma
Nexus Pharmaceuticals
Nichi-Iko
Nippon Chemiphar
Novartis (Sandoz)
Novo Nordisk
OptiMedica (Abbott)
Orchid Chemicals & Pharmaceuticals
Oriel Therapeutics (Novartis)
Parenteral Drugs India Ltd
Perrigo
Pfizer
Piramal (Abbott Laboratories)
Pliva (Teva)
PT Soho Global Health
Ranbaxy (Sun Pharmaceuticals)
Rimsa
Roche
Sabex (Novartis)
Sanofi
Sawai Pharmaceuticals
Schein Pharmaceutical (Actavis)
Shelys (Aspen)
Sigma Pharmaceuticals (Aspen)
Solvay Pharmaceuticals (Abbott)
Specifar Pharmaceuticals (Actavis)
STADA Arzneimittel
Sun Pharma
Synthon
Takeda
Taiyo Pharmaceuticals
Teuto Brasileiro (Pfizer)
Teva
The Laboratory Of Analytical Services International Ltd
Towa
UDL Laboratories
Uteron Pharma (Actavis)
Valeant Pharmaceuticals
Wal-Mart
Warner Chilcott (Actavis)
Wockhardt
Wyeth (Pfizer)
Zentiva (Sanofi)
Zhejiang Chiral Medicine Chemicals Co. Ltd
Zhejiang Hisun Pharmaceutical
Zydus Cadila
Organisations Mentioned in the Report
Assogenerici [Italy]
Blue Cross Blue Shield Association (BCBSA) [US]
British Generic Manufacturers Association (BGMA)
Caisse Nationale de l'Assurance Maladie (CNAM) [France]
Center for Drug Evaluation and Research (CDER) [US]
Centers for Medicare and Medicaid Services [US]
China Food and Drug Administration (CFDA)
COFEPRIS [Mexico]
Competion and Markets Authority (CMA) [UK]
Congressional Budget Office (CBO) [US]
European Commission
European Generics Medicines Association (EGA)
European Medicines Agency (EMA)
European Patent Office (EPO)
Federal Trade Commission (FTC) [US]
Federal Commission for the Protection against Sanitary Risk (COFEPRIS)
Food and Drugs Administration (FDA) [US]
Gesund-heits-bericht-erstat-tung des Bundes (Federal Health Monitoring System, Germany)
General Adminsistratioon of Quality Supervision, Inspection and Quarantine (AQSIQ) [China]
General Directorate of Pharmaceuticals and Pharmacy (GDPP) [Turkey]
Medicine and Healthcare products Regulatory Agency (MHRA)
Ministry of Health, Labour and Welfare (MHLW) [Japan]
Ministry of Human Resources and Social Security (MOHRSS)
National Development and Reform Commission (NDRC)
National Health Service (NHS)
National Pharmaceutical Pricing Authority [India]
Pan American Health Organization (PAHO)
Pharmaceutical and Medical Devices Agency (PMDA) [Japan]
Queen Mary University of London
Servicio Sanitario Nazionale (SSN) [Italy]
United Nations' Department of Economic and Social Affairs
US Generic Pharmaceutical Association (GPhA)
Veropharm (Abbott)
World Health Organization (WHO)
World Trade Organisation (WTO)
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain Ltd
Advertisement
Growth in Leading Regional and National Markets
What can be expected from the Generic Drugs Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.
Our 306-page report provides 175 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across all the major regional and national generic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Advertisement
Forecasts from 2016-2026 and other analyses show you commercial prospects Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments.
See detailed profiles or revenue forecasts for some of the leading regions in the generic drugs market US EU5 Asia-Pacific Emerging markets
See revenue forecasts for the leading international markets How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets, including: US Germany UK France Italy Spain China Japan India Brazil Russia Mexico South Korea Turkey
To see a report overview please email Sara Peerun on [email protected]
Leading companies and potential for market growth Visiongain forecasts overall revenue for the Generic Drugs Market will reach $254.6bn in 2016. We predict a high revenue growth over the forecast period driven by an ageing population, healthcare cost saving strategies and rapid growth of emerging economies.
Our work analyses the key companies in the market. See visiongain's analysis of ten leading companies, including: Teva Novartis (Sandoz) Allergan Mylan Pfizer Abbott Sun Pharma Aspen Fresenius Kabi Sanofi
A company profile gives you the following information where available: Discussion of a company's activities and outlook Generic drugs revenue and share of total revenue Historic revenue (where available), analysis and discussion of company performance Analysis of major products currently on the market Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the generic drugs industry? Our new report discusses issues and events affecting the generic drugs market. You will find discussions, including qualitative analyses: Highly fragmented and competitive market with significant variations in different geographic regions Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities Future generic drug opportunities
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets report helps you In summary, our 306-page report gives you the following knowledge: Revenue forecasts to 2026 for the Generic Drugs market - discover the industry's prospects, finding promising places for investments and revenues Revenue forecasts to 2026 for major regional markets - US, EU5, Asia-Pacific, Emerging markets Revenue forecasts to 2026 for fourteen leading national markets - US, Germany, UK, France, Italy, Spain, China, Japan, India, Brazil, Russia, Mexico, South Korea and Turkey Assessment of leading companies - analysis of products, revenue (where available), mergers & acquisitions, and pipelines Discussion of what stimulates and restrains companies and the market Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the generic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.
To see a report overview please email Sara Peerun on [email protected]
To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100
Or click on https://www.visiongain.com/Report/1630/Generic-Drugs-Market-Forecast-2016-2026
Companies Mentioned in the Report
Abbott
AbbVie
Actavis
Alcon (Novartis)
Allergan (Actavis)
Amgen
Anda Inc
APP Pharmaceuticals
Arrow Group (Actavis)
Ascent Pharmahealth (Actavis)
ASKA Pharmaceuticals
Aspen
AstraZeneca
Bergamo (Amgen)
Bioniche Pharma (Mylan)
BMP Sunstone (Sanofi)
CFR Pharmaceuticals (Abbott)
Cipla
Dabur Pharma (Fresenius Kabi)
Daiichi Sankyo
Dalim BioTech
Dr Reddy's Laboratory
Ebewe Pharma (Novartis)
Eden Biopharm Group
Egis
Elder Pharmaceuticals (Torrent Pharmaceuticals)
Eli Lilly
Elyson Pharmaceuticals
EMS Sigma Pharma
Eurofarma Laboratories
Farmacias Similares
Fenwal (Fresenius Kabi)
Forest Laboratories (Actavis)
Foshan Chanbende Development
Fougera Pharmaceuticals (Novartis)
Fresenius Kabi
Fresenius SE & Co
Fuji Pharma
Gedeon Richter
Genfar S.A (Sanofi)
Genzyme (Sanofi)
Gilead Sciences
GlaxoSmithKline (GSK)
Greenstone (Pfizer)
Grupo Sanborns
Grupo Uriach
Hospira (Pfizer)
IDEV Technologies (Abbott)
Ilsung Pharmaceuticals
InnoPharma Inc
Itero Biopharmaceuticals
Janssen
Javelin Pharmaceuticals (Hospira)
Kmart
KMS Pharmaceutical
Kowa Pharmaceuticals
Krka
Labesfal Genιricos (Fresenius Kabi)
Laboratorio Sanderson (Fresenius Kabi)
Laboratorios Best
Laboratorios Kendrick (Sanofi)
Lek (Novartis)
Lupin
Mayne Pharma (Hospira)
Medley (Sanofi)
Merck KGaA
MN Pharma (Amgen)
Momenta Pharmaceuticals
Mylan
Natco Pharma
Nexus Pharmaceuticals
Nichi-Iko
Nippon Chemiphar
Novartis (Sandoz)
Novo Nordisk
OptiMedica (Abbott)
Orchid Chemicals & Pharmaceuticals
Oriel Therapeutics (Novartis)
Parenteral Drugs India Ltd
Perrigo
Pfizer
Piramal (Abbott Laboratories)
Pliva (Teva)
PT Soho Global Health
Ranbaxy (Sun Pharmaceuticals)
Rimsa
Roche
Sabex (Novartis)
Sanofi
Sawai Pharmaceuticals
Schein Pharmaceutical (Actavis)
Shelys (Aspen)
Sigma Pharmaceuticals (Aspen)
Solvay Pharmaceuticals (Abbott)
Specifar Pharmaceuticals (Actavis)
STADA Arzneimittel
Sun Pharma
Synthon
Takeda
Taiyo Pharmaceuticals
Teuto Brasileiro (Pfizer)
Teva
The Laboratory Of Analytical Services International Ltd
Towa
UDL Laboratories
Uteron Pharma (Actavis)
Valeant Pharmaceuticals
Wal-Mart
Warner Chilcott (Actavis)
Wockhardt
Wyeth (Pfizer)
Zentiva (Sanofi)
Zhejiang Chiral Medicine Chemicals Co. Ltd
Zhejiang Hisun Pharmaceutical
Zydus Cadila
Organisations Mentioned in the Report
Assogenerici [Italy]
Blue Cross Blue Shield Association (BCBSA) [US]
British Generic Manufacturers Association (BGMA)
Caisse Nationale de l'Assurance Maladie (CNAM) [France]
Center for Drug Evaluation and Research (CDER) [US]
Centers for Medicare and Medicaid Services [US]
China Food and Drug Administration (CFDA)
COFEPRIS [Mexico]
Competion and Markets Authority (CMA) [UK]
Congressional Budget Office (CBO) [US]
European Commission
European Generics Medicines Association (EGA)
European Medicines Agency (EMA)
European Patent Office (EPO)
Federal Trade Commission (FTC) [US]
Federal Commission for the Protection against Sanitary Risk (COFEPRIS)
Food and Drugs Administration (FDA) [US]
Gesund-heits-bericht-erstat-tung des Bundes (Federal Health Monitoring System, Germany)
General Adminsistratioon of Quality Supervision, Inspection and Quarantine (AQSIQ) [China]
General Directorate of Pharmaceuticals and Pharmacy (GDPP) [Turkey]
Medicine and Healthcare products Regulatory Agency (MHRA)
Ministry of Health, Labour and Welfare (MHLW) [Japan]
Ministry of Human Resources and Social Security (MOHRSS)
National Development and Reform Commission (NDRC)
National Health Service (NHS)
National Pharmaceutical Pricing Authority [India]
Pan American Health Organization (PAHO)
Pharmaceutical and Medical Devices Agency (PMDA) [Japan]
Queen Mary University of London
Servicio Sanitario Nazionale (SSN) [Italy]
United Nations' Department of Economic and Social Affairs
US Generic Pharmaceutical Association (GPhA)
Veropharm (Abbott)
World Health Organization (WHO)
World Trade Organisation (WTO)
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain Ltd
